Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Hyperfine
HYPR
Hyperfine
Supply Disruptions And Delayed Adoption Will Undermine Long-Term Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
15 Aug 25
Updated
15 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$0.68
90.4% overvalued
intrinsic discount
15 Aug
US$1.30
Loading
1Y
24.5%
7D
-6.8%
Author's Valuation
US$0.7
90.4% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$0.7
90.4% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-89m
24m
2019
2021
2023
2025
2027
2028
Revenue US$23.9m
Earnings US$3.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
21.86%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.47%
Calculation
US$2.99m
Earnings '28
x
27.11x
PE Ratio '28
=
US$81.06m
Market Cap '28
US$81.06m
Market Cap '28
/
99.55m
No. shares '28
=
US$0.81
Share Price '28
US$0.81
Share Price '28
Discounted to 2025 @ 7.48% p.a.
=
US$0.66
Fair Value '25
